Rituximab biosimilar - Intas Biopharmaceuticals
Alternative Names: MabtasLatest Information Update: 14 Jan 2022
At a glance
- Originator Intas Biopharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 02 May 2013 Launched for Chronic lymphocytic leukaemia in India (IV)
- 02 May 2013 Launched for Non-Hodgkin's lymphoma in India (IV)
- 19 Oct 2011 Phase-III clinical trials in Non-Hodgkin's lymphoma in India (IV)